
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences is in a strong position with two highly differentiated gene editing programs in HBV and DMD, supported by robust data from the virtual NDR and EASL. With potential for a year-end 2026 PBGENE-HBV update at AASLD and first-patient dosing in PBGENE-DMD, investors look forward to 2026 key near-term inflections. While both programs come with high-risk/high-reward given limited near-term dataset size, the fundamentally differentiated mechanisms and promising dataset support a positive outlook for the company.
Bears say
Precision BioSciences is a clinical-stage gene editing company that utilizes its ARCUS platform to develop in vivo gene therapies for sophisticated gene edits. However, despite promising preclinical data for its PBGENE-DMD functional dystrophin gene restoration program, there are concerns about the limited addressable market and the high costs associated with gene therapy development. Additionally, the lack of a clear path to profitability and potential competition from other gene editing companies may pose risks to the company's financial performance.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares